Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Additionally, a weight loss of more than 25% was achieved in 40.4% of patients receiving CagriSema, compared to 16.2% of patients receiving semaglutide 2.4 mg, 6% of patients receiving cagrilintide 2.4 mg and 0.9% of patients receiving placebo
Adems, la disminucin anual del filtrado glomerular (eGFR) fue menos pronunciada en el grupo de semaglutida
Here's what could derail the thesis: Regulatory & Pricing Pressure Government price controls on GLP-1 drugs (Trump administration deal includes price cuts) Medicare/Medicaid coverage expansion requires discounting International pricing pressures as volumes increase Competition Intensifying Novo Nordisk fighting back with oral GLP-1 programs Amgen, Pfizer, and others entering the space Compounding pharmacies eating market share during supply shortages Operational Challenges Manufacturing constraints still limiting supply in some markets CVS formulary changes disrupted Zepbound access temporarily Volume growth partially offset by 10% lower realized prices in Q3 Valuation Risk At ~$930B market cap, expectations are sky-high Any guidance miss or pipeline disappointment will be punished severely Forward P/E of ~42 leaves little room for error Pipeline Execution Orforglipron approval timing uncertain Alzheimer's market adoption slower than hoped Clinical trial failures in crowded pipeline Smart investors acknowledge risks while staying focused on the long-term thesis
Clinical trials of VNS in obesity related diseases Multiple neuromodulation clinical trials for obesity and obesity related conditions have been conducted (Table 1)
US$ 23.71
US$ 23.83
US$ 20.83
US$ 25.72
US$ 25.93
